X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Digoxin | A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. | ILX:0103260 | 4 | scicrunch | 06/12/2021 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Digoxin Immune Fab | Sheep antibody (26-10) FAB fragment specific to Digoxindicarboxymethylamine (MW | ILX:0103261 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dihydroergotamine | A 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. (PubChem) Pharmacology: Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors. Mechanism of action: Two theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. Drug type: Approved. Small Molecule. Drug category: Analgesics. Analgesics, Non-Narcotic. Anti-migraine Agents. Dopamine Agonists. Sympatholytics. Vasoconstrictor Agents | ILX:0103262 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dihydropteridine reductase | A protein that is a translation product of the QDPR gene or a 1:1 ortholog thereof. It is an enzyme that catalyzes the reduction of 6,7-dihydropteridine to 5,6,7,8-tetrahydropteridine in the presence of NADP+. It is an important side reaction in the synthesis of DOPA from Tyrosine.(Adapted from PRO and Medical Subject Headings). | ILX:0103263 | 7 | scicrunch | 10/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dihydrotachysterol | A vitamin D that can be regarded as a reduction product of vitamin D2. (PubChem) Pharmacology: Dihydrotachysterol is hydroxylated in the liver to 25-hydroxydihydrotachysterol, which is the major circulating active form of the drug. It does not undergo further hydroxylation by the kidney and therefore is the analogue of 1, 25-dihydroxyvitamin D. Dihydrotachysterol is effective in the elevation of serum calcium by stimulating intestinal calcium absorption and mobilizing bone calcium in the absence of parathyroid hormone and of functioning renal tissue. Dihydrotachysterol also increases renal phosphate excretion. Mechanism of action: Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor) also stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone. Drug type: Approved. Small Molecule. Drug category: Antihypocalcemic Agents. Antihypoparathyroid Agents. Bone Density Conservation Agents. Vitamins. Vitamins (Vitamin D) | ILX:0103264 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DiI | Fluorescent carbocyanine dye that is highly lipophilic | ILX:0103265 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dilated | Made wider or larger in all dimensions. | ILX:0103266 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Diltiazem | A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of the calcium ion in membrane functions. It is also teratogenic. (PubChem) Pharmacology: Diltiazem, a benzothiazepine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Diltiazem is similar to other peripheral vasodilators. Diltiazem inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. Mechanism of action: Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, dilitiazem, like verapamil, inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Calcium Channel Blockers. Calcium-channel blocking agents. Cardiovascular Agents. Vasodilator Agents | ILX:0103267 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Diluted | A concentration which is relatively low. | ILX:0103268 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dimenhydrinate | Dimenhydrinate (Dramamine, Gravol and Vertirosan) is an over-the-counter drug used to prevent motion sickness. It is closely related to diphenhydramine HCl, or Benadryl. It is primarily a H1-antagonist, but also possesses an antimuscarinic effect. Pharmacology: Dimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Mechanism of action: The mechanism by which some antihistamines exert their antiemetic, antimotion sickness, and antivertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Drug type: Approved. Small Molecule. Drug category: Antiemetics. Histamine H1 Antagonists | ILX:0103269 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dimension Index Pointer | Contains the Data Element Tag that is used to identify the Attribute connected with the index. | ILX:0103270 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dimension Index Private Creator | Identification of the creator of a group of private data elements. | ILX:0103271 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dimension Index Sequence | Identifies the sequence containing the indices used to specify the dimension of the multi-frame object. Zero or more Items may be included in this sequence. | ILX:0103272 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dimension Index Values | Contains the values of the indices defined in the Dimension Index Sequence (0020,9222) for this multi-frame header frame. | ILX:0103273 | 8 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dimension Organization Sequence | Sequence that lists the Dimension Organization UIDs referenced by the containing SOP Instance. Zero or more Items may be included in this Sequence. | ILX:0103274 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dimension Organization UID | Uniquely identifies a set of dimensions referenced within the containing SOP Instance. See section C.7.6.17.2 of the DICOM standard for further explanation. | ILX:0103275 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dimeric dimer ion channel | ILX:0103276 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dimeric ion channel | ILX:0103277 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dimethyl sulfoxide | A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation. (PubChem) Pharmacology: Dimethyl Sulfoxide may have anti-inflammatory, antioxidant and analgesic activities. Dimethyl Sulfoxide also readily penetrates cellular membranes. The membrane-penetrating ability of dimethyl sulfoxide may enhance diffusion of other substances through the skin. For this reason, mixtures of idoxuridine and dimethyl sulfoxide have been used for topical treatment of herpes zoster in the United Kingdom. Mechanism of action: The mechanism of dimethyl sulfoxide's actions is not well understood. Dimethyl sulfoxide has demonstrated antioxidant activity in certain biological settings. For example, the cardiovascular protective effect of dimethyl sulfoxide in copper-deficient rats is thought to occur by an antioxidant mechanism. It is also thought that dimethyl sulfoxide's possible anti-inflammatory activity is due to antioxidant action. Drug type: Approved. Small Molecule. Drug category: Analgesics, Non-Narcotic. Cryoprotective Agents. Free Radical Scavengers. Solvents | ILX:0103278 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dimethylthiambutene | Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug. It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available. Pharmacology: Not Available Mechanism of action: Not Available Drug type: Experimental. Illicit. Small Molecule. Drug category: Analgesics, Opioid | ILX:0103279 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X